Trials / Terminated
TerminatedNCT03869593
Role of the NLRP3 Inflammasome in Escherichia Coli and Staphylococcus Aureus Bacteria
- Status
- Terminated
- Phase
- —
- Study type
- Observational
- Enrollment
- 60 (actual)
- Sponsor
- Centre Hospitalier Universitaire de Nice · Academic / Other
- Sex
- All
- Age
- 8 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Our previous studies delineate a novel pathway of immune activation in animals that the investigators have named Anti-Virulence Immunity (AVI). Using a mice model of bacteremia, the investigators have demonstrated that Escherichia coli Cytotoxic Necrotizing Factor 1 (CNF1) activity is sensed by the immune system. This immune sensing results in a rapid bacterial clearing during bacteremia triggered by uropathogenic E. coli-expressing CNF1. The investigators already confirmed the involvement of one inflammasome using macrophages isolated from Knock-out mice. The investigators have recently determined the conservation in human monocytes of the interleukin -1beta maturation triggered by CNF1 and observed the heterogeneous capacity of monocytes to respond to the CNF1 treatment depending on the donors. Here, to determine the importance in natura of AVI the investigators will analyze the blood content of patients presenting E. coli and S. aureus bacteremia. The DNA of monocytes isolated from patients will be extracted and various genes implicated in the activity of various inflammasomes will be sequenced to identify mutations that could explain the susceptibility to bacteremia or a specific clinical presentation, i.e. requirement of a management in ICU because of organ failure.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| GENETIC | Sample analysis | Here, to determine the importance of the mutation we will analyze the blood content of patients presenting E. coli and S. aureus bacteremia |
Timeline
- Start date
- 2019-06-03
- Primary completion
- 2022-03-22
- Completion
- 2023-09-01
- First posted
- 2019-03-11
- Last updated
- 2026-03-24
Locations
3 sites across 1 country: France
Source: ClinicalTrials.gov record NCT03869593. Inclusion in this directory is not an endorsement.